This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

Browse

Dexedrine

Emerging

Pure d-amphetamine — same active drug as Vyvanse but without prodrug protection, slightly cleaner peripheral profile than Adderall (no…

Aliases (7)

Dextroamphetamine · Dextroamphetamine Sulfate · Zenzedi · ProCentra · Dexedrine Spansule · d-amphetamine · (S)-(+)-amphetamine

TYPICAL DOSE

5-10 mg

Daily

ROUTE

Oral (tablet)

Oral

CYCLE

if used

As prescribed

STORAGE

Room temp; original container

Room temp

Overview

What is Dexedrine?

Dexedrine is a brand name for dextroamphetamine sulfate, the d-isomer of amphetamine, FDA-approved for ADHD and narcolepsy. Available as IR tablets and Spansule sustained-release capsules.

Key Benefits

Treats ADHD core symptoms with a more focused, less anxious profile than mixed amphetamine salts (Adderall). Useful for narcolepsy and treatment-resistant fatigue. Spansule provides ~8-hour coverage.

Mechanism of Action

Dextroamphetamine reverses DAT and NET to release dopamine and norepinephrine into the synapse, while inhibiting VMAT2 and weakly inhibiting MAO. Pure d-isomer biases toward dopaminergic effects vs racemic amphetamine.

Pharmacokinetics

PeakHalf-life

Approximate curve — visual aid only, not data-precise PK

▸Brand options5 known

DextroamphetamineDextroamphetamine SulfateZenzediProCentraDexedrine Spansule

StatusSchedule II (US DEA) | Schedule 8 (Australia) | Class B (UK) | Class III (Canada CDSA)

Peptide Interactions

L-tyrosine

Synergistic

substrate replenishment for sustained dopamine synthesis; theoretical basis for blunting late-day crash. Modest evidence.

Magnesium

Synergistic

counters NMDA-glutamate excitotoxicity, may reduce bruxism and anxiety.

L-theanine

Synergistic

anxiolytic counter to peripheral stim load.

MAOIs (selegiline, phenelzine, tranylcypromine, moclobemide)

Avoid

hypertensive crisis risk. Even low-dose (1-2.5 mg) selegiline carries this concern. Hard contraindication.

SSRIs / SNRIs

Avoid

serotonin syndrome risk plus CYP2D6 inhibition (fluoxetine, paroxetine especially) elevates d-amphetamine plasma levels.

Bupropion

Avoid

additive dopaminergic + seizure threshold lowering + CYP2D6 inhibition.

Other stimulants

Avoid

(Adderall, Vyvanse, methylphenidate, modafinil at high dose) — additive cardiovascular load + dopamine downregulation.

Alcohol

Avoid

masks intoxication, cardiovascular load.

Quality Indicators

✓

Pharmacy-dispensed, intact packaging

Prescription tablets in original sealed packaging from a licensed pharmacy.

Generic vs branded

Generics are usually fine but bioavailability can vary slightly; track if you switch.

✗

Unbranded blister or counterfeit risk

Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.

What to Expect

Day 1
PK-driven acute peak per administration. Verify dose tolerated.
Week 1
Steady-state reached for most daily-dosed pharma.
Week 2-4
Therapeutic effect established; titration window if needed.
Long-term
Periodic monitoring per drug class (labs, BP, ECG as applicable).

Side Effects & Safety 14

Side Effects

1Appetite suppression (often significant — bigger issue for combat-sport / grappling training calorie needs)
2Insomnia / delayed sleep onset (incompatible with the user's late-chronotype migration plan)
3Dry mouth
4Increased BP and HR (smaller than Adderall on average, but real)
5Headache
6Weight loss
7Anxiety / nervousness
8Mood elevation that may feel artificial
9Bruxism (jaw clenching) — less than Adderall but present
10Tachycardia / palpitations
11Vasoconstriction (cold extremities, Raynaud-like)
12Tics / motor stereotypies (especially in adolescents)
13Erectile dysfunction at higher doses
14Mood lability / irritability on taper

When to Stop

Sudden cardiac death — FDA black-box. Risk concentrated in patients with structural heart disease, family history of sudden cardiac death, or pre-existing arrhythmia. Baseline-healthy young adults at low absolute risk but non-zero.
Stroke / MI — same population, same risk profile.
Stimulant psychosis — paranoid/psychotic symptoms at high doses or in vulnerable individuals.
Cardiomyopathy — chronic high-dose use, isolated case reports.
Serotonin syndrome when combined with serotonergic drugs (SSRIs, MAOIs, MDMA).
Dependence + withdrawal — physical and psychological. Withdrawal: anhedonia, hypersomnia, depressed mood, hyperphagia, vivid dreams. Therapeutic-dose discontinuation in compliant patients usually mild; abuse-pattern discontinuation can be brutal.
First 4 weeks: monitor BP, HR, anxiety, sleep
Months 2-6: tolerance assessment + dose creep watch
Annual: ECG if any cardiac flag; cardiovascular risk reassessment